Dark

CRL
Charles River Laboratories International, Inc.
stock NYSE

At Close

Jul 27, 2026 3:59:59 PM EDT

224.21USD-1.046%(-2.37)720,332

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 24, 2026 8:06:30 AM EDT

232.79USD+2.741%(+6.21)0

After-hours

Jul 27, 2026 4:10:30 PM EDT

224.30USD+0.040%(+0.09)87,965

OverviewOptionsHistoricalExchangesShortsNews

Jan 27, 2022

08:18AM EST Charles River Expands Strategic Partnership With SAMDI Tech Benzinga

Jan 19, 2022

09:16AM EST Charles River, Valo Health Announce Strategic Partnership To Provide Clients With Access To AI-Enabled Drug Discovery Solutions Benzinga

Jan 11, 2022

08:30AM EST Charles River Laboratories International, Inc. (CRL) said on Tuesday that its Chief Financial Officer or CFO David Smith will retire from the service, once the company names a successor and the transition period gets completed, which is expected to occur before the end of 2022. RTTNews

07:18AM EST Charles River Labs CFO David Smith To Retire RTTNews

07:15AM EST Charles River Laboratories Sees FY22 Adj. EPS $11.50$11.75 vs $11.46 Est. Benzinga

07:13AM EST Charles River Laboratories Corporate Executive Vice President & Chief Financial Officer David R. Smith To Retire; Co. Initiates Successor Search Benzinga

Dec 8, 2021

09:56AM EST Virpax Posts Toxicology, Pharmacokinetic Data For Pain Med Epoladerm Benzinga

Nov 11, 2021

07:23AM EST Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer Benzinga

Nov 4, 2021

09:45AM EDT Morgan Stanley Maintains Overweight on Charles River, Lowers Price Target to $465 Benzinga

Nov 3, 2021

09:16AM EDT Charles River Q3 EPS $2.70 Beats $2.58 Estimate, Sales $895.90M Miss $903.20M Estimate Benzinga

09:16AM EDT Charles River Laboratories International Narrows FY21 EPS Guidance From $10.10-$10.35 To $10.20-$10.30 Vs. $10.25 Est. Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

07:58AM EDT While reporting financial results for the first quarter on Tuesday, Charles River Laboratories International, Inc. (CRL) raised its earnings and adjusted earnings guidance for the full-year 2021, primarily to reflect a lower-than-expected tax rate. RTTNews

07:20AM EDT Charles River Laboratories Q3 GAAP EPS $2.01 And Non-GAAP EPS $2.70 RTTNews

Oct 20, 2021

08:15AM EDT Charles River Laboratories Plans To Increase CRADL Capacity In Cambridge Benzinga

Oct 18, 2021

09:19AM EDT Charles River And ATEM Structural Discovery Announce Strategic Partnership To Provide Clients With Cryo-EM Capabilities Benzinga

Oct 15, 2021

10:00AM EDT UPDATE: KeyBanc On Charles River Overweight Reiteration: Firm Sees Increase In 'Booking Projects Months Into The Future' Indicating Favorable Supply/Demand Dynamic; Highlights Cognate & Vigene Acquisitions Driving Entry Into Cell/Gene Therapy CDMO Space Benzinga

09:43AM EDT KeyBanc Reiterates Overweight Rating On Charles River Laboratories International Inc. With $450 Price Target Benzinga

Aug 17, 2021

10:02AM EDT How Does Charles River's Debt Look? Benzinga

09:36AM EDT UBS Maintains Buy on Charles River, Raises Price Target to $465 Benzinga

Aug 4, 2021

08:07AM EDT Charles River Raises FY21 Adj. EPS Guidance From $9.75$10.00 To $10.10$10.35 vs $9.95 Est. Benzinga

08:04AM EDT Charles River Q2 Adj. EPS $2.61 Beats $2.38 Estimate, Sales $914.61M Beat $880.65M Estimate Benzinga

07:50AM EDT While reporting financial results for the first quarter on Tuesday, Charles River Laboratories International, Inc. (CRL) raised its earnings, adjusted earnings and revenue growth guidance for the full-year 2021, based on stronger-than-expected second quarter financial performance and expected robust client demand trends for the remainder of the year. RTTNews

07:49AM EDT Recap: Charles River Q2 Earnings Benzinga

07:14AM EDT Charles River Laboratories Q2 GAAP EPS $1.72 And Non-GAAP EPS $2.61 RTTNews

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Jul 20, 2021

11:38AM EDT Where Charles River Stands With Analysts Benzinga

08:23AM EDT Credit Suisse Maintains Neutral on Charles River, Raises Price Target to $385 Benzinga

Jul 12, 2021

10:14AM EDT Stocks That Hit 52-Week Highs On Monday Benzinga

Jun 7, 2021

08:10AM EDT Duke Energy Sustainable Solutions Begins Construction Of 250MW Pisgah Ridge Solar Project In Navarro County, Texas RTTNews

08:00AM EDT Duke Energy Sustainable Solutions will build its largest solar project to date: PR Newswire

May 28, 2021

10:18AM EDT Citigroup Maintains Neutral on Charles River, Raises Price Target to $355 Benzinga

09:14AM EDT Credit Suisse Maintains Neutral on Charles River, Raises Price Target to $352 Benzinga

09:02AM EDT JP Morgan Maintains Overweight on Charles River, Raises Price Target to $390 Benzinga

May 25, 2021

09:25AM EDT Truist Securities Maintains Buy on Charles River, Raises Price Target to $369 Benzinga

May 17, 2021

01:17PM EDT Charles River Acquires Viral Vector Player For $350M Benzinga

07:32AM EDT Charles River Laboratories International, Inc. (CRL) announced Monday that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. RTTNews

07:06AM EDT Charles River To Acquire Vigene Biosciences RTTNews

07:04AM EDT Charles River Laboratories to Acquire Vigene Biosciences for $292.5M Cash Benzinga

May 14, 2021

05:50AM EDT Keybanc Maintains Overweight on Charles River, Raises Price Target to $360 Benzinga

May 10, 2021

08:58PM EDT Charles River Labs To Replace FLIR Systems In S&P 500 RTTNews

06:38PM EDT Charles River Laboratories International Set to Join S&P 500; Others to Join PR Newswire

05:20PM EDT Charles River Laboratories International Set To Join S&P 500 Benzinga

May 4, 2021

07:46AM EDT Charles River: Q1 Earnings Insights Benzinga

07:30AM EDT While reporting financial results for the first quarter on Tuesday, Charles River Laboratories International, Inc. (CRL) raised its earnings, adjusted earnings and revenue growth guidance for the full-year 2021, based on stronger-than-expected first quarter financial performance and robust client demand trends for the remainder of the year. RTTNews

07:18AM EDT Charles River Q1 EPS $2.53 Beats $2.19 Estimate, Sales $824.60M Beat $798.18M Estimate Benzinga

07:14AM EDT Charles River Q1 EPS $1.20, Up 17.6% From $1.02 Last Year RTTNews

Apr 15, 2021

03:10AM EDT Carl Data Solutions (CSE: CRL) announces new capital, team members, PR Newswire

Apr 9, 2021

05:00AM EDT Carl Data Solutions (CSE: CRL) brings machine-learning to the $4.2 trillion PR Newswire

Apr 6, 2021

08:17AM EDT Charles River Labs Reports Strategic Partnership With Valence Discovery 'to provide clients access to Valence's artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization' Benzinga

Mar 31, 2021

07:49AM EDT Early-stage contract research company Charles River Laboratories International, Inc. (CRL) acquired Retrogenix Limited, an early-stage contract research organization for about 35 million pounds in cash, Charles River said in a release. RTTNews

07:05AM EDT Charles River Laboratories Acquires Retrogenix For 35M Benzinga

07:04AM EDT Charles River Laboratories Acquires Retrogenix Limited RTTNews

Mar 10, 2021

09:05AM EST Virpax Signs Agreement With Charles River Laboratories To Initiate Investigational New Drug Enabling Studies For Epoladerm Benzinga

Feb 25, 2021

08:25AM EST Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies Benzinga

Feb 22, 2021

08:57AM EST Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $350 Benzinga

Feb 18, 2021

11:13AM EST Truist Securities Maintains Buy on Charles River, Raises Price Target to $324 Benzinga

10:56AM EST Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $334 Benzinga

08:52AM EST A Look Into Charles River's Debt Benzinga

Feb 17, 2021

07:37AM EST Charles River Laboratories International, Inc. (CRL) reported fourthquarter earnings per share on a non-GAAP basis of $2.39, an increase of 18.9% from last year. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $2.10, for the quarter. Analysts' estimates typically exclude special items. RTTNews

07:35AM EST Charles River: Q4 Earnings Insights Benzinga

07:18AM EST Charles River Laboratories To Buy Cognate BioService For $875 Mln In Cash RTTNews

07:15AM EST Charles River Laboratories Sees Non-GAAP EPS $9-$9.25 Vs Est $8.34-$9.35 Benzinga

07:14AM EST Charles River Laboratories To Acquire Cognate BioServices For ~$875M In Cash Benzinga

07:12AM EST Charles River Laboratories Q4 GAAP EPS $2.81 And Non-GAAP EPS $2.39 RTTNews

07:11AM EST Charles River Q4 EPS $2.39 Beats $2.10 Estimate, Sales $791.00M Beat $756.86M Estimate Benzinga

04:34AM EST Earnings Scheduled For February 17, 2021 Benzinga

Feb 16, 2021

10:19AM EST A Preview Of Charles River's Earnings Benzinga

Jan 28, 2021

08:07AM EST Charles River Labs Reports Strategic Partnership With Cypre Benzinga

Jan 14, 2021

08:12AM EST Charles River Labs Reports Partnership With JADE Biomedical To Expand Biologics Capabilities, No Terms Disclosed Benzinga

Jan 4, 2021

07:24AM EST Charles River Laboratories Acquires Distributed Bio For $83M In Cash Benzinga

Dec 16, 2020

09:25AM EST Citigroup Downgrades Charles River to Neutral Benzinga

Dec 9, 2020

08:00AM EST Charles River Delivers Industry-First Deciphex Patholytix Digital Pathology Peer Review for GLP Studies Business Wire

Nov 24, 2020

08:41AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

03:43AM EST KeyBanc Maintains Overweight on Charles River, Raises Price Target to $256 Benzinga

Nov 12, 2020

08:18AM EST Charles River, Strategic Partner, PathoQuest, Report Establishment Of US Subsidiary, PathoQuest Inc., To Construct Next-Gen Sequencing-Based Testing Lab At Charles River's Site In Wayne, Pennsylvania Benzinga

08:00AM EST Charles River and PathoQuest Strengthen Strategic Partnership Business Wire

Nov 7, 2020

02:07PM EST Last Week's Notable Insider Buys: Cboe, IBM, Xerox And More Benzinga

Oct 30, 2020

08:39AM EDT Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260 Benzinga

Oct 29, 2020

07:58AM EDT While reporting financial results for the third quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its earnings, adjusted earnings and revenue growth guidance for the full-year 2020, due to the better-than-expected third quarter performance. RTTNews

07:47AM EDT Charles River Laboratories Q3 GAAP EPS $2.03 And Non-GAAP EPS $2.33 RTTNews

07:41AM EDT UPDATE: Charles Rivers Raises FY20 Guidance: Sales Growth From 7.5-9% To 9.5-10.5%, Adj. EPS From $7.05-$7.35 To $7.75-$7.85 vs $7.26 Estimate Benzinga

07:38AM EDT Charles River Q3 Adj. EPS $2.33 Beats $1.80 Estimate, Sales $743.30M Beat $716.36M Estimate; Raises Guidance Benzinga

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Sep 14, 2020

09:18AM EDT Argus Research Maintains Buy on Charles River, Raises Price Target to $235 Benzinga

Sep 10, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 10, 2020 Benzinga

08:14AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

05:36AM EDT Jefferies Upgrades Charles River to Buy, Raises Price Target to $254 Benzinga

Aug 18, 2020

08:18AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

04:51AM EDT KeyBanc Maintains Overweight on Charles River, Raises Price Target to $233 Benzinga

Aug 6, 2020

08:36AM EDT Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $245 Benzinga

06:58AM EDT Citigroup Maintains Buy on Charles River, Raises Price Target to $255 Benzinga

Aug 5, 2020

07:58AM EDT While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) raised its earnings, adjusted earnings and revenue growth guidance for the full-year 2020, due to the better-than-expected second quarter performance and lower-than-expected revenue loss from the COVID-19 pandemic. RTTNews

07:53AM EDT Charles River: Q2 Earnings Insights Benzinga

07:38AM EDT Charles River Q2 GAAP EPS $1.34 And Non-GAAP EPS $1.58 RTTNews

07:26AM EDT Charles River Laboratories Raises FY20 Adj. EPS Guidance From $6.75$7.10 To $7.05$7.35 vs $6.91 Est. Benzinga

07:24AM EDT Charles River Q2 Adj. EPS $1.58 Beats $1.26 Estimate, Sales $682.58M Beat $641.63M Estimate Benzinga

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga